Blog

Jul 13, 2025, 17:11

Alessandro Inno: First-Line Chemoimmunotherapy Combinations in Metastatic NSCLC with PD-L1 Less Than 50%

Alessandro Inno, Head of Clinical Trials and Translational Research in Oncology at Medical Oncology Unit at IRCCS Ospedale Sacro Cuore Don Calabria, shared a post on LinkedIn about recent article he and colleagues co-authored, published on Springer Nature Link.

“New Publication Alert

I’m excited to share our multicenter observational study, recently published in Cancer Immunology, Immunotherapy (Springer Nature):

“Real‑world effectiveness and safety of first‑line chemoimmunotherapy combinations in metastatic non‑small cell lung cancer with PD‑L1 < 50%”

Conducted across Italy, the study enrolled 495 patients with metastatic NSCLC and PD‑L1 < 50%, treated with:

Pembrolizumab + chemotherapy (348 patients)
Nivolumab/ipilimumab + chemotherapy (147 patients)

Key outcomes:

Median PFS: 10.9 months (95% CI: 9.6–13)
Median OS: 21.1 months (95% CI: 16.8–not reached)
No significant differences in effectiveness (PFS or OS) were observed between the two treatment groups

Prognostic factors linked to shorter survival:

ECOG performance status ≥ 2
PD‑L1 < 1%
Squamous histology
Baseline steroid use
CNS, bone, or liver metastases

Toxicity highlights:

Pembrolizumab + chemo was associated with more chemotherapy-related side effects
Nivolumab/ipilimumab + short-course chemo showed higher incidence of immune-related adverse events

Conclusion: In a real-world setting, both chemo‑immunotherapy regimens demonstrated solid effectiveness and manageable toxicity, in line with pivotal phase‑III trials—each with distinct safety profiles.

A big thank you to all co-authors and participating centers for their invaluable collaboration.”

Title: Real-world effectiveness and safety of first-line chemoimmunotherapy combinations in metastatic non-small cell lung cancer with programmed death ligand-1 < 50%: results from an Italian observational study

Authors: Alessandro Inno, Antonello Veccia, Ettore D’Argento, Floriana Morgillo, Elio Gregory Pizzutilo, Fabiana Vitiello, Alberto Pavan, Fiorella Lombardo, Marco Russano, Vincenzo Sforza, Francesca Colamartini, Carlo Genova, Rita Chiari, Antonella Cristofano, Alessandro Delconte, Emanuela Vattemi, Alessandra Dessi, Daniele Galanti, Simona Busato, Giovanni Palazzolo, Clementina Savastano, Antonio Bianco, Francesco Verderame, Cristina Mazzi, Fabiana Marchetti, Stefania Kinspergher, Denis Occhipinti, Carminia Maria Della Corte, Daniele Piscazzi, Marina Gilli, Emilio Bria, Orazio Caffo, Stefania Gori

Read The Full Article at Springer Nature Link.

Alessandro Inno: First-Line Chemoimmunotherapy Combinations in Metastatic NSCLC with PD-L1 Less Than 50%

More Posts Featuring NSCLC.

Alberto Pavan Alessandra Dessi Alessandro Delconte Alessandro Inno Antonella Cristofano Antonello Veccia Antonio Bianco cancer Carlo Genova Carminia Maria Della Corte Clementina Savastano Cristina Mazzi Daniele Galanti Daniele Piscazzi Denis Occhipinti Elio Gregory Pizzutilo Emanuela Vattemi Emilio Bria Ettore D'Argento Fabiana Marchetti Fabiana Vitiello Fiorella Lombardo Floriana Morgillo Francesca Colamartini Francesco Verderame Giovanni Palazzolo Marco Russano Marina Gilli NSCLC OncoDaily Oncology Orazio Caffo Rita Chiari Simona Busato Stefania Gori Stefania Kinspergher Vincenzo Sforza

New Paper Alert: Breakthrough iNKT Cell Therapy Achieves Complete Remission in Metastatic Germ Cell Tumor

Yüksel Ürün: Science Is Better When It’s Shared

Oliver Bogler: Grant Tips

Marty Makary: FDA Has Published More than 200 Complete Response Letters

In Memory of Zelig Eshhar: The Man Who Taught T Cells to Fight Cancer